Please login to the form below

tenofovir disoproxil

This page shows the latest tenofovir disoproxil news and features for those working in and with pharma, biotech and healthcare.

MSD claims EU approval for two HIV products

The pair – non-nucleoside reverse transcriptase inhibitor (NNRTI) Pifeltro (doravirine) and single-tablet combination Delstrigo (doravirine, lamivudine and tenofovir disoproxil fumarate) – are a much-needed bolster for Merck’s HIV portfolio,

Latest news

ViiV chalks up another win for two-drug HIV regimen

effects. Last month for example, ViiV showed that an oral formulation of Tivicay with nucleoside RTI Epivir (lamivudine) was as effective as a three-drug cocktail of dolutegravir plus tenofovir disoproxil ... Gilead’s new fixed-dose Biktarvy
GSK two-drug trial in untreated HIV raises Gilead rivalry

The combination of integrase inhibitor Tivicay (dolutegravir) with nucleoside reverse transcriptase inhibitor Epivir (lamivudine) had similar efficacy to treatment with dolutegravir plus tenofovir disoproxil fumarate and emtricitabine – two
ViiV starts trial of HIV-preventing injections for women

can defend against the spread of the virus as well as daily dosing with Gilead’s oral pre-exposure prophylaxis (PrEP) therapy Truvada (emtricitabine and tenofovir disoproxil).
People at-risk of HIV in England could get PrEP from September

The study of Gilead's pre-exposure prophylaxis (PrEP) therapy Truvada (emtricitabine and tenofovir disoproxil) - which was approved by the EMA last year - follows a pilot that saw the drug prevent
Gilead plans fightback against HIV arch-rival ViiV

The fixed dose combination of integrase strand inhibitor bictegravir with the two active ingredients in Descovy - emtricitabine and tenofovir alafenamide - met its main objective of non-inferiority to ViiV Healthcare's ... The drug is an upgrade to

More from news
Approximately 5 fully matching, plus 35 partially matching documents found.

Latest Intelligence

Choices, choices: the rapidly evolving HIV treatment landscape

With Triumeq signalling the approval of the first STR without tenofovir disoproxil fumarate (TDF) it can, uniquely, be used in those patients with impaired kidney function. ... Gilead, in hot pursuit, is in phase III of development of a new regimen where

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Project/ Events Manager – Medical Education and Events Agency: Salary TBC

Senior Medical Writer: Great salary and benefits

Project Manager/ Account Manager: Salary TBC

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Senior Medical Writer: Salary TBC

Account Manager, MedicalCommunications/ Healthcare PR: benefits

AD – Corporate Comms/ Public Affairs/ B2B – Healthcare Focus: Salary TBC

PR Director – Health & Wellbeing – Mat Cover (4 days a week)...: Salary TBC

Account/ Project Director – Medical Affairs – Surrey: Salary TBC

Senior Medical Writer: Up to £50, 000 with Benefits

Senior Planner – Healthcare Advertising – New Role: Salary TBC

Account Director, Medical Education: Salary TBC

Account Director, Healthcare Marketing Agency: Salary TBC

Editorial Assistant Medical Education Agency: £25, 000 - £26, 000

Digital Account Director: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

International Childhood Cancer Day 2019: The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues: Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups: A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...